TechneScan sales to start in Sweden

Article

Radiopharmaceutical developer Mallinckrodt Medical said that itwill begin sales in Sweden of TechneScan Q12, a technetium-basedcardiac imaging agent, following approval of the agent by Sweden'shealth authorities. Sweden is the first country in the

Radiopharmaceutical developer Mallinckrodt Medical said that it

will begin sales in Sweden of TechneScan Q12, a technetium-based

cardiac imaging agent, following approval of the agent by Sweden's

health authorities. Sweden is the first country in the European

Union to approve TechneScan, and certifications in other European

nations are expected. St. Louis-based Mallinckrodt filed a new

drug application for the product in the U.S. in 1994.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.